Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 20, Issue 4, 1999, Pages 376-381

  Sendi, Peter P ^a   Bucher, Heiner C ^a,d   Craig, Bruce A ^b   Pfluger, Dominik ^c   Battegay, Manuel ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d KANTONSSPITAL BASEL   (Switzerland)

Author keywords

AIDS epidemiology; Anti HIV agents; Disease progression; Markov chains; Switzerland

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MODEL; PRIORITY JOURNAL; SURVIVAL RATE; SWITZERLAND;

EID: 0033040536     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199904010-00008     Document Type: Article

References (14)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
2. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1997; 351:543-9.
3. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-9.
4. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
5. Palella FJJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
6. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-58.
7. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
8. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:1-20.
9. Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Präventivmed 1994;39:387-94.
10. Raboud JM, Haley L, Montaner JS, Murphy C, Januszewska M, Schechter MT. Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(Suppl 2):S67-73.
11. Efron B, RJ Tibshirani. An introduction to the bootstrap: monographs on statistics and applied probability 57. New York: Chapman & Hall, 1993.
12. Craig BA, Fryback DG, Klein R, Klein BEK. A Bayesian approach to modeling the natural history of a chronic condition from observations with intervention. Stat Med (in press).
13. Aalen OO, Farewell VT, De Angelis D, Day NE, Gill ON. A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: application to AIDS prediction in England and Wales. Stat Med 1997;16:2191-2210.
14. + cell counts in HIV-infected patients. The Swiss HIV Cohort Study. Arch Intern Med 1998;158:247-52.